Do compression garments improve symptoms in adult women with pelvic congestion syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Compression Garments for Pelvic Congestion Syndrome

Class II compression shorts (not stockings) can provide symptomatic relief for women with pelvic congestion syndrome and chronic pelvic pain, reducing pain scores by approximately 80% and improving pelvic venous hemodynamics, but they should be considered a temporizing measure rather than definitive treatment.

Evidence for Compression Therapy

The most direct evidence comes from a prospective study that specifically evaluated compression garments in 74 women with pelvic congestion syndrome 1. This study demonstrated:

  • Class II compression shorts reduced chronic pelvic pain from 6.4 ± 1.6 to 1.2 ± 0.7 points (on a 10-point scale) in 81.3% of patients
  • The coefficient of pelvic congestion syndrome decreased from 1.73 ± 0.32 to 1.12 ± 0.27 (p < 0.05)
  • Treatment duration was 14 days

Critical distinction: Class II compression stockings alone showed NO effect on pelvic congestion syndrome symptoms or hemodynamics 1. The compression must be applied to the pelvic region itself (shorts), not just the lower extremities.

When Compression May Be Appropriate

Compression shorts may serve as:

  • Initial conservative management while awaiting definitive diagnosis or treatment
  • Adjunctive therapy in patients with both pelvic congestion and vulvar varicosities (combined shorts and stockings) 1
  • Temporizing measure for patients who decline or are not candidates for endovascular intervention

However, 18.8% of patients showed no response to compression therapy 1, indicating it is not universally effective.

Definitive Treatment Remains Endovascular

The 2024 consensus statement from major vascular societies emphasizes that endovascular treatment (ovarian vein embolization and/or iliac vein stenting) is the primary therapeutic approach for pelvic congestion syndrome 2. Recent case series demonstrate:

  • 86.8% symptom improvement with gonadal embolization 3
  • 70.8% reduction in dyspareunia and 72.4% reduction in dysmenorrhea 3
  • Immediate and sustained relief following endovascular treatment 4

The 2025 French expert consensus reinforces that endovascular embolization is the primary treatment approach after thorough imaging evaluation 5.

Clinical Algorithm

  1. Confirm diagnosis with invasive venography and IVUS showing >50% area reduction or >61% diameter stenosis 2
  2. Identify underlying pathology: reflux (gonadal/internal iliac vein), compression (IVCS, Nutcracker syndrome), or combined 2, 4
  3. Consider Class II compression shorts as initial conservative management for 2 weeks if:
    • Patient has isolated pelvic pain without vulvar involvement
    • Awaiting definitive intervention
    • Patient preference for conservative trial
  4. Proceed to endovascular treatment (embolization ± stenting) for definitive management, especially if:
    • Compression fails after 2 weeks
    • Combined reflux and obstruction present 2
    • Significant quality of life impairment

Important Caveats

  • Do not use compression stockings alone - they are ineffective for pelvic congestion 1
  • Compression provides symptomatic relief but does not address underlying venous pathology
  • Nearly 20% of patients will not respond to compression therapy 1
  • The general sports medicine literature on compression garments 6 is not applicable to pelvic congestion syndrome, as it addresses different mechanisms and anatomical regions

The evidence supports using Class II compression shorts as a conservative option, but clinicians should maintain a low threshold for proceeding to endovascular treatment given its superior and durable outcomes 3, 4, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.